Skip to main content

Table 3 Characteristics of patients in the KyberSept trial

From: Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

 

Overall population*

All 90-day survivors

90-day in-hospital

Parameter

Placebo (n = 1157)

AT III (n = 1157)

Placebo (n = 437)

AT III (n = 460)

Placebo (n = 55)

AT III (n = 63)

Age (years; mean ± SD [range])

58 ± 17 (18–96)

57 ± 17 (18–93)

53 ± 17 (18–96)

53 ± 17 (18–88)

57 ± 15 (22–81)

56 ± 14 (21–79)

Sex (%)

      

   Male

61

62

62

64

67

65

   Female

39

38

38

36

33

35

Country (%)

      

   USA

15

15

14

15

6

6

   Czech Republic

11

11

12

11

18

10

   South Africa

11

11

9

8

2

5

   UK

8

8

9

9

13

13

   Denmark

7

7

6

7

6

11

   Germany

6

6

6

5

4

8

   Other (13 countries)

40

40

43

46

53

48

SAPS II risk group (%)

      

   Moderate risk (<30%)

27

29

43

40

24

24

   High risk (30–60%)

45

42

40

43

36

41

   Very high risk (>60%)

28

29

17

18

40

35

Admitting diagnosis (%)†

      

   Respiratory system

34

35

33

34

33

24

   Digestive system

28

27

29

27

38

40

   Genitourinary system

8

6

11

8

4

2

   Injury

6

7

5

7

0

10

   Other

24

24

22

25

26

25

Concomitant heparin (%)

      

   No

30

30

29

32

13

30

   Yes

70

70

71

68

87

70

  1. *All 2314 patients evaluable for efficacy in KyberSept study. †According to the International Classification of Diseases (9th edition). Percentages may not add to 100 because of rounding. AT, antithrombin; SAPS, Simplified Acute Physiology Score.
Back to article page

Critical Care

ISSN: 1364-8535